Background: Evidence for the effects of Parkinson disease on energy expenditure is incom-
| INTRODUCTION
Unexplained loss of weight in the early phases of Parkinson disease (PD) is common. 1 In cases of normal (or even increased) caloric intake in early PD, 1,2 the cause of weight loss in this phase of the disease is often assumed to be increased energy expenditure. This hypothesis has been supported by certain studies that have reported increased energy expenditure in PD, 3, 4 but disconfirmed by others. 2, 5 These conflicting findings may be associated with differences in the use of dopaminergic agents, the severity of the disease, body composition, and/or unmatched gender between PD and control groups. Some studies have not made a distinction between resting energy expenditure and activity-induced energy expenditure, and the experimental procedures were not designed to address these putative differences.
To better understand energy expenditure in PD, we measured oxygen consumption (V O 2 ) at rest and during moderate aerobic effort under optimally controlled conditions, in a homogeneous group of PD male patients, naive to dopaminergic therapy, in the early phase of the disease. To reduce the variability among participants (percentage of fat tissue, muscle mass, and hormonal state), we only enrolled males in this study.
| METHODS

| Participants
This choice was guided by the higher percentage of muscle mass in males, which enabled us to detect subtle differences in a relatively small sample in energy consumption related to fat-free mass (FFM), which consists largely of muscle tissue. The patients with PD were not on dopaminergic therapy (levodopa or agonists). Two of the PD patients were on symptomatic therapy (amantadine), and 6 were taking MAO-B inhibitors.
The participants were assessed on the Motor Unified Parkinson 0 s Disease Rating Scale (UPDRS) on the day of the test. The level of regular physical activity was evaluated using the Physical Activity Scale for the Elderly 6 and was similar between groups (t test P > .11 for all questions; seeTable S1). To exclude unrelated factors that can alter baseline metabolism, participants were instructed to avoid eating (4 h), drinking caffeinated beverages (2 h), and smoking (2 h) before the procedure. 
| Measurement of FFM and oxygen consumption
The FFM measurement was calculated for each patient by bioelectrical impedance analysis using a body composition monitor (Tanita model BC-545, Tanita Corporation, Tokyo, Japan). The body composition monitor was validated against dual-energy X-ray absorptiometry 8 prior to the test. Indirect calorimetry was performed by measuring V O 2 (oxygen consumption) using a metabolic cart with a built-in spiroergometry (Zan 600, nSpire Health GmbH, Oberthulba, Germany), which measures breath-by-breath oxygen consumption and carbon dioxide output.
| Spirometry procedures
To assess resting energy expenditure, participants sat in a comfortable armchair, with their torso leaning back at 50 to 70 degrees, for 10 minutes.
All respired air was collected by a well-fitted face mask. Calculations were based on the measurements obtained at minutes 8 to 10 (steady state).
Average values of V O 2 in liters per minute were multiplied by 4.9 to calculate caloric consumption in kilocalorie per minute and again by 1440
(number of min per 24 h) to calculate daily resting energy expenditure.
We then measured V O 2 in 4 sequential conditions-3 minutes of relaxed sitting on the bike, 4 minutes of unloaded cycling (no resistance, constant cycling speed 60 rpm), and 6 minutes of 40-W loaded cycling (constant cycling speed 60 rpm). This was followed by a 4-minute recovery period in which participants stopped cycling but continued to sit relaxed on the bike. The working load was well below the anaerobic threshold of all participants and ensured steady-state conditions. The respiratory exchange ratio was similar between groups and did not exceed 0.9.
During exercise, the patients 0 blood pressure, oxygen saturation, and electrocardiography were monitored. Visual inspection of the V O 2 graphs revealed that during these time intervals, oxygen consumption was stable.
| Statistics
Our experiment (10 individuals in each arm) was designed to detect at least a 20% increment of energy expenditure in the PD group (1-sided test with P < .1), assuming intra-group standard deviation of 20% of the group 0 s mean with a power of 80%.
| RESULTS
We measured the energy expenditure of 10 male patients with early PD and compared their results against 10 matched individuals without PD (participant characteristics are summarized in Table 1 The physical tasks were increasingly demanding. When sitting in the armchair, both the axial and limb muscles were largely inactivated. 
| DISCUSSION
By measuring oxygen consumption, we showed that in a homogenous population of males with early PD who were not on dopaminergic therapy, the energy expenditure at rest did not increase. Physical activity, on the other hand, led to an increment in energy expenditure that was higher than in the controls. Evidence for abnormally increased energy expenditure emerged from the recruitment of axial muscles to support the body trunk in a sitting posture.
Our observation of normal resting energy expenditure in PD is consistent with previous studies 2,5 but conflicts with others. 3, 4 These contradictory results may have to do with unmatched PD and control group gender, 3 a lack of adjustment for FFM, 4 or the recruitment of patients on medication that modulates metabolic rate such as beta-blockers or thyroid hormone replacement therapy or individuals who had undergone deep brain stimulation. 9 We avoided these issues by only testing male patients (for their higher proportion of FFM), matching for anthropomorphic parameters, and excluding patients on potentially confounding medication or post-PD surgeries.
Daily energy expenditure, which sums both resting energy expenditure and the energy consumption induced by physical activity, was found to be lower in PD than in the non-affected controls when was 
